Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.18T
Market cap1.18T
Price-Earnings ratio
41.07
Price-Earnings ratio41.07
Dividend yield
0.55%
Dividend yield0.55%
Average volume
2.14M
Average volume2.14M
High today
$1,275.88
High today$1,275.88
Low today
$1,223.00
Low today$1,223.00
Open price
$1,238.87
Open price$1,238.87
Volume
3.75M
Volume3.75M
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$783.85
52 Week low$783.85

Stock Snapshot

With a market cap of 1.18T, Eli Lilly(LLY) trades at $1,252.10. The stock has a price-to-earnings ratio of 41.07 and currently yields dividends of 0.55%.

During the trading session on 2026-10-15, Eli Lilly(LLY) shares reached a daily high of $1,275.88 and a low of $1,223.00. At a current price of $1,252.10, the stock is +2.4% higher than the low and still -1.9% under the high.

Trading activity shows a volume of 3.75M, compared to an average daily volume of 2.14M.

The stock's 52-week range extends from a low of $783.85 to a high of $1,292.65.

The stock's 52-week range extends from a low of $783.85 to a high of $1,292.65.

LLY News

Quartz 2h
Eli Lilly stock gains more than 3% as investors shift from tech to healthcare - Quartz

...

Eli Lilly stock gains more than 3% as investors shift from tech to healthcare - Quartz
The Motley Fool 5h
Stock Split Watch: Is Eli Lilly Next?

Eli Lilly (LLY +4.82%), as a pharmaceutical stock, may be seen as a source of safety for investors — patients need their medicines, and this provides a certain...

Stock Split Watch: Is Eli Lilly Next?
TipRanks 6h
Lilly Targets KRAS G12C in Colorectal Cancer With New Phase 2 Trial

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The study, run by Eli Lilly And Company (LLY), is a Phase 2 trial called “A St...

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
9.1%
Sell
6.1%

More LLY News

TipRanks 6h
Lilly’s Donanemab Moves Into India: What This New Alzheimer’s Study Means for Investors

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The Phase 4 study “A Phase 4, Multicenter, Open-Label, Single-Arm Study to Eva...

TipRanks 6h
Lilly’s Lebrikizumab Eczema Study Wraps Up, Adding Real‑World Support to Its Immunology Story

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The Phase 4 study A Phase 4, Multicenter, Open-label, Single-arm Study to Inve...

Benzinga 7h
Eli Lilly Says New Drug Drives Comprehensive Disease Control in Ulcerative Colitis Patients

Eli Lilly and Co. (NYSE:LLY) on Thursday revealed new data demonstrating that Omvoh (mirikizumab-mrkz) helps patients with moderately to severely active ulcerat...

Eli Lilly Says New Drug Drives Comprehensive Disease Control in Ulcerative Colitis Patients
TipRanks 11h
Adlai Nortye enters CTCSAs with Eli Lilly, Merck KGaA for cetuximab

Adlai Nortye (ANL) announced clinical trial collaboration and supply agreements, or CTCSAs, with Eli Lilly (LLY) and Merck KGaA (MKGAF) for the anti-EGFR antibo...

TipRanks 1d
Lilly’s Tersolisib Food‑Effect Study Marks Quiet But Important Pipeline Progress

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The Phase 1 study “A Study of Food Effect on Tersolisib (LY4064809) in Healthy...

Simply Wall St 2d
Eli Lilly Psoriasis Data Tests Whether Its Valuation Story Still Has Room

Eli Lilly (LLY) just put fresh clinical data on the table, showing that combining Taltz and Zepbound shifted more psoriasis and metabolic biomarkers than Taltz...

Eli Lilly Psoriasis Data Tests Whether Its Valuation Story Still Has Room
The Motley Fool 2d
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Healthcare investors often face a choice between steady value and high-octane growth. Choosing between Bristol Myers Squibb (BMY -1.58%) and Eli Lilly & Co. (LL...

Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.